Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$369.35 - $548.43 $861,324 - $1.28 Million
2,332 New
2,332 $1.15 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $260,049 - $305,755
760 New
760 $288,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track O'Neil Global Advisors, Inc. Portfolio

Follow O'Neil Global Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Neil Global Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on O'Neil Global Advisors, Inc. with notifications on news.